RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

Phase 1approvedRXIM002Positive

AI Analysis

Summary

RiboX Therapeutics announced FDA IND clearance for RXIM002, described as the first circular RNA-based in vivo CAR-T therapy, enabling initiation of a Phase 1 clinical trial for autoimmune cytopenias.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND clearance granted

Importance:7/10

Sentiment:

0.85

circular RNACAR-T therapyin vivo therapyLNP deliveryautoimmuneIND clearance

Related Companies

$TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on August 8, 2026 7:46 AM

Read Original